0000000000524666
AUTHOR
F. Giancola
Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study
Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…
Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?
Osteonecrosis of the jaw (ONJ) is a rare but serious lesion of the jaw, characterized mainly by exposed necrotic bone;it is related to various drugs, usually used for treating patients with advanced malignancies. Drugs implicated in ONJ are: nitrogen-containing bisphosphonates (NBPs), denosumab, anti-angiogenic drugs (e.g bevacizumab, sunitinib,sorafenib) and the selective mammalian target of rapamycin mTOR, everolimus. Previous data regarding the combining of NBPs with antiangiogenic agents conflict with some reports (indicating a similar risk of ONJ compared with the use of NBPs alone1); other reports show significantly higher rates (18% vs 1% with NBPs alone) of the incidence of ONJ2. Th…
THE ROLE OF HIGH-DOSE VITAMIN D IN RISK REDUCTION OF OSTEONECROSIS OF THE JAW IN CANCER PATIENTS RECEIVING ZOLEDRONIC ACID
Osteonecrosis of the jaw (ONJ) is a serious complication of oncological patients after or during drug therapy, whose manifestations range from asymptomatic to aspects requiring extensive operative treatment and adversely affecting patient’s qualify of life. Taking in account that the lack of supplementation vitamin D causes hypovitaminosis, increasing bone renewal, losing bone mass, and in severe cases determing osteomalacia (one of the risk factors for ONJ) and that the probability of developing ONJ increases significantly during the first 3 years of treatment, the main objective of the present study is to assess whether the implementation of high-dose vitamin D in oncologic patients treat…
Dual localization of oral Kaposi’s sarcoma in HIV-negative patient: a rare case report
Not available
BRONJ in patients with rheumatoid arthritis: A multicenter case series
Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…